Live Nasdaq Composite: Cautious Optimism Takes Hold as Chip Stocks Rebound and SpaceX IPO Nears

Health and Healthcare

Health and Healthcare Articles

All Health and Healthcare Articles

5865 Articles

Jon C. Ogg | Sep 12, 2016 at 12:45 PM EDT

Is Geron Being Overly Punished?

Investors never like to see a stock they own drop 17%, but there is at least one view that maybe…

Douglas A. McIntyre | Sep 12, 2016 at 9:15 AM EDT

The 25 States Where Medical Marijuana Is Legal

It is presumed that states where medical marijuana is legal will be the most likely to have laws that provide…

Chris Lange | Sep 12, 2016 at 8:55 AM EDT

Why Horizon Pharma Is Not Overpaying for Raptor Pharma

If we look at what Horizon is paying, it doesn’t necessarily add up, using the numbers from this year, but…

Chris Lange | Sep 11, 2016 at 10:35 AM EDT

4 Key BioPharma Movers in the Past Week

Some biotech companies made impressive runs over the course of this past week. These select few stood out from the…

Douglas A. McIntyre | Sep 10, 2016 at 9:05 AM EDT

How Obesity and Smoking Add $142 Billion to US Health Care Costs Annually

The primary conclusion of a recent study about the cost of obesity and smoking in America is that they add…

Chris Lange | Sep 9, 2016 at 9:45 AM EDT

Why Lexicon Pharma Is Soaring

Lexicon Pharmaceuticals rallied Friday on late-stage results from a pivotal Phase 3 clinical trial of a type 1 diabetes treatment.

Douglas A. McIntyre | Sep 9, 2016 at 9:15 AM EDT

American Heath Deteriorated During Obama Administration

The most recent Gallup-Healthways study shows that well-being in the United States dropped during the Obama administration.

Chris Lange | Sep 8, 2016 at 12:50 PM EDT

Why Repros Is Rising

Shares of Repros Therapeutics climbed in Thursday’s session after the company announced results from its mid-stage study for women with…

Jon C. Ogg | Sep 8, 2016 at 12:35 PM EDT

Evaluating a GW Pharma Merger, Maybe

24/7 Wall St. has been concerned about the longer-term implications of GW Pharma over other emerging drug and biotech outfits.

Chris Lange | Sep 8, 2016 at 8:05 AM EDT

Key FDA Decisions and Trial Results Expected in October

24/7 Wall St. has collected several big FDA decisions and mid-to-late-stage trials that should be coming up in October. These…

Chris Lange | Sep 7, 2016 at 12:10 PM EDT

Did Agios Just Speed Up Its Business Plan by 2 Years?

Celgene is making a move out of left field that has sent shares of its partner Agios Pharmaceuticals significantly higher.

Chris Lange | Sep 7, 2016 at 11:10 AM EDT

Is the FDA Changing Its Tune on Evoke Pharma?

Evoke Pharma shares saw a handy gain on Wednesday following news of a positive meeting with the FDA over Gimoti.

Chris Lange | Sep 7, 2016 at 8:35 AM EDT

Why Retrophin Shares Have Soared

Shares of Retrophin climbed early on Wednesday following positive top-line news from its mid-stage trial for the treatment of focal…

Jon C. Ogg | Sep 6, 2016 at 3:51 PM EDT

Why This Major Disappointment May Not Mark the End for Tonix Pharmaceuticals

Tonix Pharmaceuticals was the disaster of the day on Tuesday after the company announced that it will stop development of…

Jon C. Ogg | Sep 6, 2016 at 2:38 PM EDT

Does Danaher’s Cepheid Deal Have More Sizzle Than Meets the Eye?

It is not uncommon for an acquirer to see its shares drop on news when it makes an acquisition. Still,…

1 … 195 196 197 198 199 … 392

Health and Healthcare Articles

All Health and Healthcare Articles

Is Geron Being Overly Punished?

The 25 States Where Medical Marijuana Is Legal

Why Horizon Pharma Is Not Overpaying for Raptor Pharma

4 Key BioPharma Movers in the Past Week

How Obesity and Smoking Add $142 Billion to US Health Care Costs Annually

Why Lexicon Pharma Is Soaring

American Heath Deteriorated During Obama Administration

Why Repros Is Rising

Evaluating a GW Pharma Merger, Maybe

Key FDA Decisions and Trial Results Expected in October

Did Agios Just Speed Up Its Business Plan by 2 Years?

Is the FDA Changing Its Tune on Evoke Pharma?

Why Retrophin Shares Have Soared

Why This Major Disappointment May Not Mark the End for Tonix Pharmaceuticals

Does Danaher’s Cepheid Deal Have More Sizzle Than Meets the Eye?

Live Nasdaq Composite: Cautious Optimism Takes Hold as Chip Stocks Rebound and SpaceX IPO Nears

Leveraged ETFs Do Work. This One Turned $10K into $3.64m in 16 Years

Nvidia Breaks Below $200, Approaches Bear Market Territory. How Much Further Can It Fall?

This AI Prodigy Has Returned 1,000% And Now Manages $20 Billion. Here’s His Most Recent Buys

Why a $1.4 Million 401(k) Makes That Side Hustle Far More Expensive Than You Think

What a $1.5 Million Dividend Portfolio Actually Pays a Retired Couple After Federal Tax, State Tax, and IRMAA

Leveraged ETFs Do Work. This One Turned $10K into $3.64m in 16 Years

Nvidia Breaks Below $200, Approaches Bear Market Territory. How Much Further Can It Fall?

Health and Healthcare Articles

All Health and Healthcare Articles

Is Geron Being Overly Punished?

The 25 States Where Medical Marijuana Is Legal

Why Horizon Pharma Is Not Overpaying for Raptor Pharma

4 Key BioPharma Movers in the Past Week

How Obesity and Smoking Add $142 Billion to US Health Care Costs Annually

Why Lexicon Pharma Is Soaring

American Heath Deteriorated During Obama Administration

Why Repros Is Rising

Evaluating a GW Pharma Merger, Maybe

Key FDA Decisions and Trial Results Expected in October

Did Agios Just Speed Up Its Business Plan by 2 Years?

Is the FDA Changing Its Tune on Evoke Pharma?

Why Retrophin Shares Have Soared

Why This Major Disappointment May Not Mark the End for Tonix Pharmaceuticals

Does Danaher’s Cepheid Deal Have More Sizzle Than Meets the Eye?

Live Nasdaq Composite: Cautious Optimism Takes Hold as Chip Stocks Rebound and SpaceX IPO Nears

Leveraged ETFs Do Work. This One Turned $10K into $3.64m in 16 Years

Nvidia Breaks Below $200, Approaches Bear Market Territory. How Much Further Can It Fall?

This AI Prodigy Has Returned 1,000% And Now Manages $20 Billion. Here’s His Most Recent Buys

Featured Reads

Why a $1.4 Million 401(k) Makes That Side Hustle Far More Expensive Than You Think

What a $1.5 Million Dividend Portfolio Actually Pays a Retired Couple After Federal Tax, State Tax, and IRMAA